Chronic Exertional Compartment SyndromePhase 2/3NCT05247541
Diagnosing Compartment Syndrome With SHAPE vs Elastography
A Phase 2/3 study testing Definity in people with Chronic Exertional Compartment Syndrome, run by Thomas Jefferson University at 1 site in United States.
Trial summary
Chronic exertional compartment syndrome (CECS) is an innocuous condition seen primarily in 10-60% of young active people with exercise induced leg pain. With an average delay in diagnosis of 2 years, early identification is crucial as delays have led to poor surgical outcomes after fasciotomy. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Exertional Compartment Syndrome
- What is being tested?
- Definity
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2020to 1 Dec 2023
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- CECS as the primary diagnosis with no other more likely diagnoses.
- Age over 18.
Who cannot join
- Medial tibial stress syndrome or tibial stress fractures diagnosed on MRI.
- Recent trauma/surgery to the lower extremity
- Pregnant
- Stress fractures of the lower extremity
- Diabetic neuropathy
- Peripheral vascular disease
Show all 10Show fewer
- Pressure ulcers or treatment for pressure ulcers
- Coronary artery disease
- Active pulmonary disease
- Allergy to any components of Definity.
Trial locations and contacts
1 site in 1 country.
United States1 site
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
About this study
Official title: Diagnosing Chronic Exertional Compartment Syndrome: Measurement of Intra-Compartmental Pressures Using Noninvasive Subharmonic Aided Pressure Estimation (SHAPE) Versus Shear Wave Elastography (SWE).
Chronic exertional compartment syndrome (CECS) is an innocuous condition seen primarily in 10-60% of young active people with exercise induced leg pain. With an average delay in diagnosis of 2 years, early identification is crucial as delays have led to poor surgical outcomes after fasciotomy. Diagnosis is currently made by compartment pressure (CP) testing, which is invasive, painful and demonstrates variable accuracy. There is no literature on the role of shear wave elastography (SWE) and/or subharmonic assisted pressure estimation (SHAPE) with microbubbles in diagnosing CECS. Ultrasound contrast agents are FDA-approved and are extremely safe. In this single-blinded prospective pilot study, the accuracy of SHAPE and SWE will be evaluated and compared to the current gold standard of compartment testing in patients with suspected CECS. Muscle stiffness and record a quantitative assessment of enhancement and hydrostatic pressures will be documented and correlated with compartment testing results based on a reference standard modified Pedowitz criteria for CECS
Read the detailed description
Chronic exertional compartment syndrome (CECS) is an innocuous condition seen primarily in 10-60% of young, active people with exercise induced leg pain. Patients present with anterior lower extremity pain that worsens with exercise and resolves after rest. CECS arises from increased intra-compartmental pressure causing impaired tissue perfusion. The average delay in diagnosis and subsequent treatment is 2 years, which has been shown to decrease the success rate of both conservative and surgical therapy. Definitive treatment is with fasciotomy, which has a success rate of up to 95%.
The etiology of CECS is not well understood but is thought to arise from volume expansion of a muscle within a noncompliant space bounded by fascia and bone resulting in insufficient blood flow and a resultant oxygen supply and demand mismatch in that compartment. In some cases the physiological response may lead to a 20% increase in muscle volume. Several risk factors have been identified including pre- existing fascial defects (seen in 40% of CECS patients) and a smaller capillary density to muscle size ratio. In rare cases, CECS may progress to acute compartment syndrome - a surgical emergency requiring emergent fasciotomy.
The gold standard for diagnosing CECS is direct measurement of intra-compartmental pressures with maximum sensitivity and specificity in recent studies of 93% and 74%. However, in rare circumstances, diagnosis can be made on clinical basis alone. Compartment pressure testing is performed by inserting a handheld large gauge needle with a pressure monitor into the muscle and measuring the compartment pressure directly (in mmHg). Direct compartment testing is invasive, painful, and carries a complication risk of neurovascular damage and infection. Furthermore, there is significant variability in this technique with some studies finding more than >5 mmHg difference in 40% of compartmental pressure measurements.
In the diagnostic algorithm of CECS, imaging is primarily used to rule out other more common causes of lower extremity leg pain such as medial tibial stress syndrome (MTSS), stress fractures, and muscle strains. Several non-invasive imaging modalities have been used to diagnose CECS. When compared to pressure testing, MRI showed similar sensitivity, but lower specificity (< 60%). While MRI has shown some diagnostic promise, it is more expensive, less ubiquitous, and less accurate than compartment testing. Near-infrared spectroscopy, which measures hemoglobin O2 saturation of tissues, has shown to have clinically equivalent sensitivies (85%) compared to compartment testing, however, it is not readily available.
A clinical exam alone is insensitive and non-specific in the diagnosis of CECS. Therefore, surgeons must rely on a combination of clinical exam and imaging to determine whether a patient is a surgical candidate. An accurate, non-invasive, and cost effective diagnostic tool does not currently exist for patients with suspected CECS. SWE is a safe, non-invasive and relatively inexpensive modality that has wide ranging diagnostic capabilities. SWE is used measure liver stiffness thereby staging fibrosis in chronic liver disease, following up previously diagnosed hepatic fibrosis and evaluating patients with portal hypertension. Recently, the utility of SWE in musculoskeletal imaging has increased; for example SWE is currently being using to evaluate tendinopahic achilles tendons with some clinical success.
FDA-approved ultrasound contrast agents are safe, non-nephrotoxic, non-hepatotoxic contrast agents that act as echo-enhancers before dissipation from the intravascular space. SHAPE utilizing microbubbles has been used for the noninvasive estimation of hydrostatic blood pressure to monitor interstitial fluid pressure in tumors, assess the degree of portal hypertension, and to monitor neoadjuvant chemotherapy for breast cancer patients. However, no series studies exist characterizing SHAPE and SWE for the screening or diagnosis of CECS. This study will assess whether SHAPE and/or SWE can accurately detect increased intra-compartmental pressures when compared to the reference standard of intra-compartmental pressure testing.
This study will be performed as a prospective single-blinded pilot study of patients with suspected CECS who is eligible to participate in the study and meets inclusion and exclusion criteria (described below). A research Coordinator will meet with the patient to explain the study in full. If the prospective subject expresses interest in participating in the study an investigator will approach the patient to obtain consent. All sonographic research portions of the study will be performed by a certified and experienced sonographer. The compartment testing portion of the study will be performed as part of the subjects standard of care.
Pre-exercise SWE: After determining inclusion, patients will undergo pre-exercise SWE using a Logiq E10 ultrasound system (GE Healthcare, Waukesha WI) with a linear array transducer. All images will be obtained with the ankle in a neutral position. Conventional B-mode imaging will be used to identify the muscle of interest. Imaging will be used to guide placement of ROIs, which can be adjusted by the operator After shear waves have propagated through the muscle of concern tissue displacement maps are used to calculate shear-wave velocity in meters per second. Elasticity parameters, including mean (Emean), maximum (Emax), minimum (Emin), and standard deviation (ESD) will be displayed on the ultrasound machine monitor. Tissue stiffness will then be directly calculated, expressed as the shear modulus G in kilopascals (kPa). Quantitative shear modulus maps will be generated.
Pre-exercise SHAPE: The modified software allowing the E10 to operate in subharmonic imaging (SHI) mode will permit acquisition of subharmonic data. All images will be obtained with the ankle in the neutral position. An 18-24 gauge intravenous line will be placed in either the right or left Upper extremity. The contrast will be an intravenous infusion of 2 vials of Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes. The route of administration and dosages follow the recommendations issued by the manufacturer. SHI will be performed using the same scanner. A broad bandwidth C2-9 convex probe will be used to acquire conventional and subharmonic images (transmitting at 5.8 MHz receiving at 2.9 MHz). The investigators will run a power optimization algorithm to establish individual acoustic parameters settings for the case (initial imaging study only). After power optimization, the Region of Interest (ROI) will be enlarged to collect data from the compartment of interest over 5 seconds and findings are averaged after processing. Both the fundamental data (B-mode data at 4 MHz) and the SHI data will be analyzed offline.
Exercise protocol: Patients will perform common exercise that causes symptoms is walking/running using a standardized exercise treadmill protocol: 3.7 mph against a 5° slope for 6 minutes or until symptom onset. If symptoms do not occur by 6 minutes of exercise, speed will be increased to a maximum of 5 mph and/or slope will be increased to 8° for an additional 6 minutes or until symptom onset. If the patient is still asymptomatic, he or she will exercise for another 4 minutes at 5 mph and an 8° slope or until symptom onset. Immediate post-exercise SWE and SHAPE will be performed using the same optimization parameters and protocol established for the pre-exercise portion of the study. Patients will be assigned a dummy code and de-identified SWE and SHI data will be stored for off line analysis.
The entire ultrasound portion of the study will last under 60 minutes and will be performed while the patient is under constant observation. The patient's vital signs will be monitored through the entire examination with frequent monitoring by the physician present. Active patient participation will conclude on completion of the study protocol.
- Conditions
- Chronic Exertional Compartment Syndrome
- Being tested
- Definity
- Medical subject headings
- Chronic Exertional Compartment Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DefinityDrug
Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
| Study group | Role | What they receive |
|---|---|---|
| Healthy Participants | Active comparator | Not described Receives: Drug: Definity |
| Study participants | Experimental | Not described Receives: Drug: Definity |
What is being measured
The primary outcome is the main question the study is designed to answer.
Accuracy in diagnosing
Evaluate the ability of SHAPE with microbubbles and SWE to accurately diagnose chronic exertional compartment syndrome (CECS) in percent using ROC analysis.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2022
- Study start1 Jul 2020
- Primary completion1 Mar 2023
- Study completion1 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Exertional Compartment SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This study will be performed as a prospective nonblinded pilot study.
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Thomas Jefferson University
- Sponsor type
- University, hospital or other
- Collaborators
- Lantheus Medical Imaging, Rothman Institute Orthopaedics
- Responsible party
- Principal investigator, Flemming Forsberg, Thomas Jefferson University
- Investigators
- Flemming Forsberg, PhD, Principal investigator, Thomas Jefferson University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05247541
- Sponsor's protocol ID
- CG20003
- Status last verified
- Dec 2023
- First submitted
- 27 Jan 2022
- Last updated
- 12 Dec 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared upon request and approval.
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnosing Chronic Exertional Compartment Syndrome: Measurement of Intra-Compartmental Pressures Using Noninvasive Subharmonic Aided Pressure Estimation (SHAPE) Versus Shear Wave Elastography (SWE).
- ClinicalTrials.gov ID
- NCT05247541
- Acronym / sponsor ID
- CG20003
- Conditions
- Chronic Exertional Compartment Syndrome
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Thomas Jefferson UniversityUniversity, hospital or other
- Collaborators
- Lantheus Medical Imaging, Rothman Institute Orthopaedics
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- 1 Mar 2023 (actual)
- Study completion
- 1 Dec 2023 (actual)
- First posted
- 21 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic exertional compartment syndrome (CECS) is an innocuous condition seen primarily in 10-60% of young active people with exercise induced leg pain. With an average delay in diagnosis of 2 years, early identification is crucial as delays have led to poor surgical outcomes after fasciotomy. Diagnosis is currently made by compartment pressure (CP) testing, which is invasive, painful and demonstrates variable accuracy. There is no literature on the role of shear wave elastography (SWE) and/or subharmonic assisted pressure estimation (SHAPE) with microbubbles in diagnosing CECS. Ultrasound contrast agents are FDA-approved and are extremely safe. In this single-blinded prospective pilot study, the accuracy of SHAPE and SWE will be evaluated and compared to the current gold standard of compartment testing in patients with suspected CECS. Muscle stiffness and record a quantitative assessment of enhancement and hydrostatic pressures will be documented and correlated with compartment testing results based on a reference standard modified Pedowitz criteria for CECS
Detailed description
Chronic exertional compartment syndrome (CECS) is an innocuous condition seen primarily in 10-60% of young, active people with exercise induced leg pain. Patients present with anterior lower extremity pain that worsens with exercise and resolves after rest. CECS arises from increased intra-compartmental pressure causing impaired tissue perfusion. The average delay in diagnosis and subsequent treatment is 2 years, which has been shown to decrease the success rate of both conservative and surgical therapy. Definitive treatment is with fasciotomy, which has a success rate of up to 95%.
The etiology of CECS is not well understood but is thought to arise from volume expansion of a muscle within a noncompliant space bounded by fascia and bone resulting in insufficient blood flow and a resultant oxygen supply and demand mismatch in that compartment. In some cases the physiological response may lead to a 20% increase in muscle volume. Several risk factors have been identified including pre- existing fascial defects (seen in 40% of CECS patients) and a smaller capillary density to muscle size ratio. In rare cases, CECS may progress to acute compartment syndrome - a surgical emergency requiring emergent fasciotomy.
The gold standard for diagnosing CECS is direct measurement of intra-compartmental pressures with maximum sensitivity and specificity in recent studies of 93% and 74%. However, in rare circumstances, diagnosis can be made on clinical basis alone. Compartment pressure testing is performed by inserting a handheld large gauge needle with a pressure monitor into the muscle and measuring the compartment pressure directly (in mmHg). Direct compartment testing is invasive, painful, and carries a complication risk of neurovascular damage and infection. Furthermore, there is significant variability in this technique with some studies finding more than >5 mmHg difference in 40% of compartmental pressure measurements.
In the diagnostic algorithm of CECS, imaging is primarily used to rule out other more common causes of lower extremity leg pain such as medial tibial stress syndrome (MTSS), stress fractures, and muscle strains. Several non-invasive imaging modalities have been used to diagnose CECS. When compared to pressure testing, MRI showed similar sensitivity, but lower specificity (< 60%). While MRI has shown some diagnostic promise, it is more expensive, less ubiquitous, and less accurate than compartment testing. Near-infrared spectroscopy, which measures hemoglobin O2 saturation of tissues, has shown to have clinically equivalent sensitivies (85%) compared to compartment testing, however, it is not readily available.
A clinical exam alone is insensitive and non-specific in the diagnosis of CECS. Therefore, surgeons must rely on a combination of clinical exam and imaging to determine whether a patient is a surgical candidate. An accurate, non-invasive, and cost effective diagnostic tool does not currently exist for patients with suspected CECS. SWE is a safe, non-invasive and relatively inexpensive modality that has wide ranging diagnostic capabilities. SWE is used measure liver stiffness thereby staging fibrosis in chronic liver disease, following up previously diagnosed hepatic fibrosis and evaluating patients with portal hypertension. Recently, the utility of SWE in musculoskeletal imaging has increased; for example SWE is currently being using to evaluate tendinopahic achilles tendons with some clinical success.
FDA-approved ultrasound contrast agents are safe, non-nephrotoxic, non-hepatotoxic contrast agents that act as echo-enhancers before dissipation from the intravascular space. SHAPE utilizing microbubbles has been used for the noninvasive estimation of hydrostatic blood pressure to monitor interstitial fluid pressure in tumors, assess the degree of portal hypertension, and to monitor neoadjuvant chemotherapy for breast cancer patients. However, no series studies exist characterizing SHAPE and SWE for the screening or diagnosis of CECS. This study will assess whether SHAPE and/or SWE can accurately detect increased intra-compartmental pressures when compared to the reference standard of intra-compartmental pressure testing.
This study will be performed as a prospective single-blinded pilot study of patients with suspected CECS who is eligible to participate in the study and meets inclusion and exclusion criteria (described below). A research Coordinator will meet with the patient to explain the study in full. If the prospective subject expresses interest in participating in the study an investigator will approach the patient to obtain consent. All sonographic research portions of the study will be performed by a certified and experienced sonographer. The compartment testing portion of the study will be performed as part of the subjects standard of care.
Pre-exercise SWE: After determining inclusion, patients will undergo pre-exercise SWE using a Logiq E10 ultrasound system (GE Healthcare, Waukesha WI) with a linear array transducer. All images will be obtained with the ankle in a neutral position. Conventional B-mode imaging will be used to identify the muscle of interest. Imaging will be used to guide placement of ROIs, which can be adjusted by the operator After shear waves have propagated through the muscle of concern tissue displacement maps are used to calculate shear-wave velocity in meters per second. Elasticity parameters, including mean (Emean), maximum (Emax), minimum (Emin), and standard deviation (ESD) will be displayed on the ultrasound machine monitor. Tissue stiffness will then be directly calculated, expressed as the shear modulus G in kilopascals (kPa). Quantitative shear modulus maps will be generated.
Pre-exercise SHAPE: The modified software allowing the E10 to operate in subharmonic imaging (SHI) mode will permit acquisition of subharmonic data. All images will be obtained with the ankle in the neutral position. An 18-24 gauge intravenous line will be placed in either the right or left Upper extremity. The contrast will be an intravenous infusion of 2 vials of Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes. The route of administration and dosages follow the recommendations issued by the manufacturer. SHI will be performed using the same scanner. A broad bandwidth C2-9 convex probe will be used to acquire conventional and subharmonic images (transmitting at 5.8 MHz receiving at 2.9 MHz). The investigators will run a power optimization algorithm to establish individual acoustic parameters settings for the case (initial imaging study only). After power optimization, the Region of Interest (ROI) will be enlarged to collect data from the compartment of interest over 5 seconds and findings are averaged after processing. Both the fundamental data (B-mode data at 4 MHz) and the SHI data will be analyzed offline.
Exercise protocol: Patients will perform common exercise that causes symptoms is walking/running using a standardized exercise treadmill protocol: 3.7 mph against a 5° slope for 6 minutes or until symptom onset. If symptoms do not occur by 6 minutes of exercise, speed will be increased to a maximum of 5 mph and/or slope will be increased to 8° for an additional 6 minutes or until symptom onset. If the patient is still asymptomatic, he or she will exercise for another 4 minutes at 5 mph and an 8° slope or until symptom onset. Immediate post-exercise SWE and SHAPE will be performed using the same optimization parameters and protocol established for the pre-exercise portion of the study. Patients will be assigned a dummy code and de-identified SWE and SHI data will be stored for off line analysis.
The entire ultrasound portion of the study will last under 60 minutes and will be performed while the patient is under constant observation. The patient's vital signs will be monitored through the entire examination with frequent monitoring by the physician present. Active patient participation will conclude on completion of the study protocol.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study will be performed as a prospective nonblinded pilot study.
| Arm | Type | Receives |
|---|---|---|
| Healthy Participants | Active comparator | Drug: Definity |
| Study participants | Experimental | Drug: Definity |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- CECS as the primary diagnosis with no other more likely diagnoses.
- Age over 18.
Key exclusion criteria (10 listed)
- Medial tibial stress syndrome or tibial stress fractures diagnosed on MRI.
- Recent trauma/surgery to the lower extremity
- Pregnant
- Stress fractures of the lower extremity
- Diabetic neuropathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DefinityDefinity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes | Drug | Healthy Participants, Study participants |
Primary outcome
Accuracy in diagnosing
Time frame: 2 years
Evaluate the ability of SHAPE with microbubbles and SWE to accurately diagnose chronic exertional compartment syndrome (CECS) in percent using ROC analysis.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2023.
- Individual participant dataSharing planned: Yes. Data will be shared upon request and approval.
Related trials for Chronic Exertional Compartment Syndrome
Recruiting
Treatment of Lower Leg Anterolateral Chronic Exertional Compartment Syndrome With Intra-muscular Botulinum Injections.
Chronic Exertional Compartment Syndrome
Recruiting
Physiotherapy or Fasciotomy as Treatment for Chronic Exertional Compartment Syndrome in the Lower Leg?
Compartment Syndrome Nontraumatic Lower Leg
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Flemming Forsberg, PhD principal investigator
Thomas Jefferson University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Definity in people with Chronic Exertional Compartment Syndrome, run by Thomas Jefferson University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Accuracy in diagnosing (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2023.